1 The circulating proteome and brain health: Mendelian randomisation and cross-sectional analyses

- 2 Rosie M. Walker PhD^{a, b, c, *}
- 3 Michael Chong PhD^{a,d*}
- 4 Nicolas Perrot PhD^a
- 5 Marie Pigeyre MD^{a,e}
- 6 Danni A. Gadd PhD^f
- 7 Aleks Stolicyn PhD^c
- 8 Liu Shi PhD^{g,h}
- 9 Archie Campbell MAⁱ
- 10 Xueyi Shen PhD^c
- 11 Heather C. Whalley PhD^{c,i}
- 12 Alejo Nevado-Holgado PhD^g
- 13 Andrew M. McIntosh MD^c
- 14 Stefan Heitmeier^j
- 15 Sumathy Rangarajan MSc^a
- 16 Martin O'Donnell^{a,k}
- 17 Eric E. Smith MD^{a, I, m, n}
- 18 Salim Yusuf DPhil^{a, e, †}
- 19 William N. Whiteley FRCP^{a, c, o, †}
- 20 Guillaume Paré MD^{a,d,p†}

- ^aPopulation Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton,
- 22 ON, Canada
- 23 ^bSchool of Psychology, University of Exeter, Perry Road, Exeter, UK
- 24 ^cCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
- ^dDepartment of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University,
- 26 Hamilton, ON, Canada
- ^eDepartment of Medicine, Michael G DeGroote School of Medicine, Faculty of Health Sciences,
- 28 McMaster University, Hamilton, ON, Canada
- ²⁹ ^fCentre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of
- 30 Edinburgh, Edinburgh, UK
- ^gDepartment of Psychiatry, University of Oxford, Oxford, UK
- 32 ^hNxera Pharma UK Limited, Cambridge, UK
- ³³ ⁱGeneration Scotland, Centre for Genomic and Experimental Medicine, Institute of Genetics and
- 34 Cancer, University of Edinburgh, Edinburgh, EH4 2XU, UK
- ^jBayer AG, Pharmaceuticals, R&D, 42113, Wuppertal, Germany
- ⁸Health Research Board Clinical Research Facility, University of Galway, Galway, Ireland
- 37 Department of Clinical Neurosciences and Hotchkiss Brain Institute, Cumming School of Medicine,
- 38 Calgary, Alberta, Canada
- ^mUniversity of Calgary, Calgary, Alberta, Canada
- 40 ⁿDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
- 41 °MRC Centre for Population Health, University of Oxford, Oxford, UK

- 42 ^pThrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences and McMaster
- 43 University, Hamilton, ON, Canada
- 44 *Joint first authors
- 45 [†]Joint final authors
- 46 Corresponding authors: <u>pareg@mcmaster.ca</u> and r.walker4@exeter.ac.uk

48 Abstract

49 Decline in cognitive function is the most feared aspect of ageing. Poorer midlife cognitive function is 50 associated with increased dementia and stroke risk. The mechanisms underlying variation in 51 cognitive function are uncertain. Here, we assessed associations between 1160 proteins' plasma 52 levels and two measures of cognitive function, the digit symbol substitution test (DSST) and the 53 Montreal Cognitive Assessment in 1198 PURE-MIND participants. We identified five DSST 54 performance-associated proteins (NCAN, BCAN, CA14, MOG, CDCP1), with NCAN and CDCP1 55 showing replicated association in an independent cohort, GS (N=1053). MRI-assessed structural 56 brain phenotypes partially mediated (8-19%) associations between NCAN, BCAN, and MOG, and 57 DSST performance. Mendelian randomisation analyses suggested higher CA14 levels might cause 58 larger hippocampal volume and increased stroke risk, whilst higher CDCP1 levels might increase 59 intracranial aneurysm risk. Our findings highlight candidates for further study and the potential for 60 drug repurposing to reduce risk of stroke and cognitive decline.

61 Acronyms: Average causal mediation effect (ACME); brevican (BCAN); carbonic anhydrase 14 (CA14); 62 cluster of differentiation 6 (CD6); CUB-domain containing protein 1 (CDCP1); confidence interval (CI); 63 cerebral microbleed (CMB); cerebrospinal fluid (CSF); digit symbol substitution test (DSST); 64 extracellular matrix (ECM); false discovery rate (FDR); Generation Scotland imaging subsample (GS); 65 Generation Scotland: Scottish Family Health Study (GS:SFHS); instrumental variable (IV); inverse 66 variance weighted (IVW); myelin oligodendrocyte glycoprotein (MOG); Montreal Cognitive 67 Assessment (MoCA); Mendelian randomisation (MR); magnetic resonance imaging (MRI); neurocan 68 (NCAN); perineuronal net (PNN); odds ratio (OR); posterior probability (PP); protein quantitative trait 69 loci (pQTL); pairwise conditional analysis and co-localisation analyses (PWCoCo); Prospective Urban 70 and Rural Epidemiology (PURE); robust adjusted profile score (RAPS); silent brain infarct (SBI); 71 standard deviation (SD); small vessel disease (SVD); white matter hyperintensity (WMH)

- 72 Key words: cognition, dementia, Alzheimer's disease, stroke, proteins, brain structure, MRI,
- 73 Mendelian randomisation

74 **1. Introduction**

Decline in cognitive ability and dementia are the most feared aspects of ageing ^[1], providing a strong rationale for investigating the mechanisms underlying cognitive function. Poorer cognitive function is associated with a greater risk of Alzheimer's dementia and stroke ^[2, 3]. This may be due to reduced "cognitive reserve", which postulates that lower premorbid cognitive function leads to worse cognitive impairment for a given degree of neuropathology ^[4]. Better understanding of these mechanisms could inform strategies for the prevention and treatment of dementia and stroke.

Recent studies have highlighted the potential for investigating cognition and structural brain phenotypes through the study of plasma proteins ^[5-9]. These studies identified associations between cognitive function and proteins involved in biological functions previously implicated in dementia, including synaptic function, inflammation, immune function, and blood-brain barrier integrity ^[5-7, 9]. At the time of carrying out this study, previous studies were limited by a focus on a restricted number of proteins and/or purely observational analyses.

Here, we investigated associations between 1160 plasma proteins and cognitive function in the Prospective Urban and Rural Epidemiology (PURE)-MIND cohort ^[10], and we sought replication in the independent imaging subsample of the Generation Scotland cohort (henceforth, referred to as "GS"). The proteins assessed represent a wide range of biological processes, permitting a hypothesis-free approach to investigating cognitive function. Subsets of these proteins have been assessed in previous studies, allowing assessment of cross-study replication.

Using a simple measure of processing speed, the digit symbol substitution task (DSST), and a cognitive screening tool, the Montreal Cognitive Assessment (MoCA), we carried out a screen for cognition-associated proteins, and then employed mediation analyses to assess the proportion of the protein expression-cognition relationship that could be explained by structural brain phenotypes, including measures of brain volume and white matter hyperintensity (WMH) volume. WMH is an MRI marker of white matter damage, and is one of the manifestations of age-related

- 99 cerebral small vessel disease. Two sample Mendelian randomisation (MR) analyses were performed
- 100 to assess potentially causal effects of genetically predicted protein levels on genetically predicted
- 101 cognitive function, brain structure, stroke subtypes, and Alzheimer's disease (see Figure 1 for an
- 102 overview of the study design).

104 2. Results

105 Cohort characteristics

106 Key demographic, cognitive, brain MRI, and health variables for the participants in PURE-MIND 107 (N=1198) and GS (N=1053) are summarised in Table 1. Participants in PURE-MIND were significantly 108 younger than participants in GS (PURE-MIND: mean = 54.5 years (SD = 8.05 years); GS: mean = 59.9 years (SD = 9.59 years); $p < 2.2 \times 10^{-16}$), and a small, but significant, between-cohort difference in 109 110 DSST score was observed (PURE-MIND: mean = 69.5 (SD = 15.3); GS: mean = 68.1 (SD = 15.2); p = 111 0.0298). Differences in the levels/types of education received by the two cohorts were observed (p =112 5×10^{-4}). The two cohorts also differed significantly on several brain volume measurements: PURE-MIND participants have a smaller total brain volume (PURE-MIND: mean = 1058 cm^3 (SD = 110 cm^3); 113 GS: mean = 1069 cm³ (SD = 109 cm³); p = 0.0212), cerebral white matter volume (PURE-MIND: mean 114 = 447 cm³ (SD = 60.5 cm³); GS: mean = 455 cm³ (SD = 56.9 cm³); $p = 1.87 \times 10^{-3}$), and hippocampal 115 volume (PURE-MIND: mean = 3.92 cm^3 (SD = 0.433 cm^3); GS: mean = 4.18 cm^3 (SD = 0.437 cm^3); $p = < 320 \text{ cm}^3$ 116 2.2 x 10-¹⁶) than GS participants, whilst GS participants have a smaller intracranial volume (ICV) than 117 PURE-MIND participants (PURE-MIND: mean = 1491 cm³ (SD = 159 cm³); GS: mean = 1400 cm³ (SD = 118 225 cm³); $p = \langle 2.2 \times 10^{-16} \rangle$. The two cohorts also differed significantly on other health-related 119 120 variables that were not directly assessed in this study (Table 1).

121 Scores on the DSST were normally distributed in both PURE-MIND and GS (Supplementary Figure 1),

122 but scores on the MoCA showed a leftward skew in PURE-MIND (Supplementary Figure 1).

123 Identification of protein biomarkers of cognitive function and enrichment analyses

Five proteins were associated with DSST performance in PURE-MIND (Figure 2; Figure 3; Supplementary Table 1; Supplementary Figure 2). Higher plasma levels of neurocan (NCAN; β = 2.03 (indicating a 2.03 higher DSST score per a standard deviation higher NCAN level), p = 9.11 x 10⁻⁸), brevican (BCAN; β = 1.91, p = 5.56 x 10⁻⁷), carbonic anhydrase 14 (CA14; β = 1.90, p = 5.90 x 10⁻⁷),

and myelin-oligodendrocyte glycoprotein (MOG; β = 1.82, p = 2.29 x 10⁻⁶), and lower levels of CUB 128 129 domain-containing protein 1 (CDCP1; β = -1.57, p = 3.97 x 10⁻⁵) were associated with significantly 130 better DSST performance. Adjustment for educational attainment modestly attenuated the effect 131 estimate for all five proteins (Supplementary Table 1). Levels of NCAN, BCAN and MOG were positively correlated (0.251 $\leq r \geq$ 0.615; all $p < 2.20 \times 10^{16}$), whilst CDCP1 and CA14 expression levels 132 were negatively correlated (r = -1.01, $p = 4.82 \times 10^{-4}$; Supplementary Table 2). Three proteins (NCAN, 133 134 BCAN and CDCP1) proteins were also measured in GS, of which two replicated their association with DSST performance: NCAN (β = 1.40, p = 1.07 x 10⁻³) and CDCP1 (β = -1.99, p = 9.21 x 10⁻⁶; Figure 3). 135 MoCA performance was not associated with the level of any protein (all $p \ge 2.34 \times 10^{-4}$; 136 137 Supplementary Table 3; Supplementary Figure 3). When considering the 129 proteins that were 138 nominally significantly associated (p < 0.05) with DSST score in PURE-MIND and measured in GS 139 (Supplementary Table 4), their effect estimates showed a strong, statistically significant betweencohort correlation (r = 0.625, $p = 2.34 \times 10^{-15}$). 140

Proteins nominally associated (p < 0.05) with DSST performance (N = 184) were enriched for brainexpressed proteins, most significantly for proteins with hippocampal expression (FDR-corrected p = 0.0154; **Supplementary Table 5**). Better DSST performance was nominally associated with lower levels of 90 proteins. These proteins mapped to the following immune pathways "interleukin-10 signalling", "glomerulonephritis", "regulation of granulocyte chemotaxis", "positive regulation of leukocyte chemotaxis", "positive regulation of leukocyte migration", and "inflammation" (FDRcorrected $p \le 0.0337$; **Supplementary Table 6**).

148 Structural brain phenotypes as mediators of protein biomarker-DSST performance associations

In PURE-MIND, better DSST performance was associated with greater cerebral white matter volume ($\beta = 0.0615$, $p = 4.34 \times 10^{-7}$), greater total brain volume ($\beta = 0.0349$, $p = 9.64 \times 10^{-6}$), greater hippocampal volume ($\beta = 2.97$, $p = 4.79 \times 10^{-3}$), and lower log-transformed WMH volume ($\beta = -3.20$, $p = 1.18 \times 10^{-6}$). These associations replicated in GS (**Supplementary Table 7**).

153 Assessment of the relationships between protein levels and DSST-associated structural brain 154 phenotypes in PURE-MIND revealed systematic differences between those proteins for which higher 155 levels were associated with better DSST performance (NCAN, BCAN, CA14, and MOG), and CDCP1, 156 which was negatively associated with DSST performance (Figure 4). Whilst NCAN, BCAN, CA14, and 157 MOG showed a positive direction of association with total brain, cerebral white matter, and 158 hippocampal volume measurements and a negative association with WMH volume, the converse 159 was true for CDCP1. The associations between NCAN levels and total brain, cerebral white matter, and hippocampal volumes reached statistical significance ($p \le 2.56 \times 10^{-5}$) and were replicated in GS 160 $(p \le 6.70 \times 10^{-3})$. BCAN levels were significantly associated with all four brain volumes $(p \le 4.36 \times 10^{-5})$ 161 162 ⁴), with the associations with total brain and cerebral white matter volumes replicating in GS ($p \leq$ 3.44 x 10^{-3}). The associations between MOG levels and total brain and cerebral white matter 163 volumes attained statistical significance ($p \le 2.63 \times 10^{-9}$), but could not be assessed in GS. We did not 164 165 identify any significant associations with CA14 or CDCP1 levels after multiple testing correction.

166 In PURE-MIND, cerebral white matter volume explained a significant proportion of variance in the 167 relationship between MOG (19.2%), BCAN (14.9%), and NCAN (12.7%) levels and DSST performance 168 (all $p < 2 \times 10^{-16}$) (Supplementary Table 8). After controlling for cerebral white matter volume, the 169 average effect estimates (based on 1000 bootstrap resamples) for these proteins were reduced from 170 1.81 to 1.47 (MOG), 1.91 to 1.62 (BCAN), and 2.03 to 1.77 (NCAN). Log-transformed WMH volume 171 was a significant partial mediator of the association between BCAN levels and DSST performance (p 172 = 0.002). Controlling for log-transformed WMH resulted in a reduction in the effect estimate from 173 1.91 to 1.75 (8% mediation).

174 Identification of potentially causal relationships between protein levels and cognitive function, 175 structural brain phenotypes, and disease outcomes

Inverse variance weighted (IVW) MR analyses were performed to assess the effects of genetically
 predicted CA14, CDCP1, and MOG levels on cognitive function, structural brain phenotypes, and

Alzheimer's disease, and stroke. Protein quantitative trait loci (pQTLs) located in *cis* to the genes encoding the proteins-of-interest acted as instrumental variables (IVs) for plasma protein levels (**Supplementary Table 9**). An insufficient number of pQTLs precluded the assessment of BCAN andNCAN with any of the outcomes-of-interest. For MOG, limited overlap between the pQTLs and SNPs included in the outcome GWASs meant only a subset of the outcomes-of-interest could be assessed.

184 A one standard deviation higher level of genetically predicted plasma CA14 was associated with a 185 larger hippocampal volume (β = 0.0971 [95% CI: 0.0300 to 0.164], p = 4.58 x 10⁻³), and a greater risk of all stroke (odds ratio (OR) = 1.08 [95% CI: 1.02 to 1.14], $p = 6.97 \times 10^{-3}$; Supplementary Table 10). 186 187 A one standard deviation higher level of genetically predicted plasma CDCP1 was associated with an 188 increased risk of intracranial aneurysm (OR = 1.22 [95% CI: 1.02 to 1.47], p = 0.0280). These 189 associations were corroborated by similar effect estimates from weighted median and MR-RAPS 190 analyses. No evidence of directional or horizontal pleiotropy were observed, and the correct causal 191 direction was assessed. No significant associations were observed between the genetically predicted 192 levels of CA14 or CDCP1 and risk of Alzheimer's disease ($p \ge 0.125$) (NB. A lack of significant pQTLs 193 precluded the assessment of BCAN, MOG, or NCAN).

Sensitivity analyses were performed in which instrumental variables (IVs) were selected using a stricter threshold for independence. For genetically predicted CA14, these analyses supported the association with hippocampal volume (β = 0.144 [95% CI: 0.0435 to 0.244], p = 4.97 x 10⁻³), and produced a consistent, although non-significant, effect estimate for the association with risk for all stroke (**Supplementary Table 10**). For CDCP1, the sensitivity analyses identified a consistent, although non-significant, effect estimate for the association with risk for analyses.

To assess whether between-population heterogeneity in pQTL effects could have affected our findings, we sought to replication using random effects meta-analysis (**Supplementary Table 10**). For genetically predicted CA14, this approach supported the significant associations with hippocampal

volume (β = 0.0953 [95% CI: 0.0586 to 0.132], *p* = 3.63 x 10⁻⁷), and risk for all stroke (OR = 1.06 [95% CI: 1.03 to 1.09], *p* = 2.56 x 10⁻⁴). For genetically predicted CDCP1, it was only possible to assess the association with risk for intracranial aneurysm using a single IV; this identified a significant association (OR = 1.32 [95% CI: 1.08 to 1.61], *p* = 6.93 x 10⁻³). Pairwise Conditional Analysis and Co-localisation Analyses (PWCoCo) were performed to assess the presence of a shared variant for each of the five proteins-of-interest and the same outcomes as assessed by two-sample MR analyses. We were only adequately powered to assess co-localisation

210 between SNPs associated with one pair of traits: MOG plasma level and cognitive function. We did

- 211 not observe any evidence in support of co-localisation or conditional co-localisation (posterior
- 212 probability (PP)4/PP3 \leq 4.81 x 10⁻⁴).

213 3. Discussion

In this large-scale analysis of the associations between the plasma levels of 1160 proteins and cognitive function, we identify CA14 and CDCP1 as being associated with processing speed, as measured by the DSST, and having potentially causal effects on hippocampal volume and stroke (CA14)and intracranial aneurysm (CDCP1).

218 Other proteins (BCAN, NCAN, and MOG) were associated with DSST performance and important 219 structural brain phenotypes, with cerebral white matter volume mediating a significant proportion 220 (13-19%) of the relationship between the levels of all three proteins and DSST performance, and 221 WMH volume mediating 8% of the relationship between BCAN levels and DSST performance. A lack 222 of genetic instruments precluded the assessment of potentially causal effects of BCAN and NCAN 223 with any outcome-of-interest, and MOG with several outcomes-of-interest.. Enrichment analyses of 224 proteins that were nominally significantly associated with DSST performance revealed a significant 225 enrichment for brain-expressed proteins.

There were no significant associations between plasma protein levels and performance on the MoCA. This might reflect the fact that the MoCA is a screening tool for mild cognitive impairment ^[11], meaning its sensitivity to detect variation in cognitive function in non-clinical groups is likely to be limited. The maximum MoCA score is 30 and scores higher than 26 indicate normal function. A high mean score (26.5) and a left-skewed distribution indicate a ceiling effect, which likely limited power to detect associations between protein levels and MoCA score in PURE-MIND.

CA14 is one of fifteen isoforms of the carbonic anhydrase family of zinc metalloprotease enzymes, which catalyse the reversible hydration of carbon dioxide ^[12]. CA14 is expressed by neurons ^[13] and involved in regulating extracellular pH following synaptic transmission ^[14, 15]. Consistent with our findings, acute inhibition of CA14 leads to impaired performance on cognitive tasks in mice ^[16]. Carbonic anhydrase activation may lead to beneficial cognitive effects in rodents ^[17]. In keeping with our MR results, there are neuroprotective effects of carbonic anhydrase inhibition in models of

amyloidosis, Huntington's disease, and ischaemic and haemorrhagic stroke ^[17]. The mechanisms by 238 which carbonic anhydrase inhibition and activation exert their effects are uncertain ^[16, 17]. FDA-239 240 approved carbonic anhydrase inhibitors, and thus the majority of carbonic anhydrase inhibitors 241 investigated to date, are pan-carbonic anhydrase inhibitors. Of the carbonic anhydrase family 242 members measured in our study (CA1, 2, 3, 4, 5A, 6, 9, 12, 13, and 14), only CA14 levels were significantly associated with DSST performance. Further studies are required to determine the 243 244 therapeutic potential for carbonic anhydrase modulation in the context of cognitive impairment, 245 Alzheimer's disease, and stroke.

246 The extracellular matrix (ECM) proteins NCAN and BCAN are brain-specific chondroitin sulfate 247 proteoglycans, which are expressed by neurons and astrocytes (NCAN and BCAN), and 248 oligodendrocytes (BCAN). They contribute to the formation of a specialised structure, the 249 perineuronal net (PNN), which plays a key role in memory and neuronal plasticity, and which is 250 disrupted in Alzheimer's disease ^[18]. Our findings are consistent with those of Harris et al. (2020) ^[5], 251 who found plasma levels of NCAN and BCAN were positively associated with brain volume. Plasma 252 levels of both NCAN and BCAN have previously been shown to be positively associated with general cognitive function and DSST performance ^[9], whilst BCAN levels have been found to be positively 253 254 associated with Mini Mental State Examination performance and reduced in patients with Alzheimer's disease or mild cognitive impairment ^[7]. Mice that are lacking either NCAN or BCAN 255 256 expression show normal development and memory function but reduced hippocampal long term potentiation ^[19, 20], whilst guadruple knock-outs, which lack NCAN, BCAN, and two additional ECM 257 258 proteins (tenascin-C and tenascin-R) show an altered ratio of excitatory to inhibitory synapses and a reduction in the number and complexity of hippocampal PNNs ^[21]. Genetic variation in the gene 259 260 encoding A Disintegrin and Metalloproteinase with Thrombospondin Motifs 4 (ADAMTS4), which 261 degrades the four members of the lectican family (including NCAN and BCAN), has been implicated in Alzheimer's disease ^[22]. Taken together, the evidence suggests NCAN, BCAN and their regulators 262 as molecules-of-interest in Alzheimer's disease. 263

264 MOG is an oligodendrocyte-expressed membrane glycoprotein, the exact function of which is 265 unknown^[23].

266 CDCP1 is a widely expressed transmembrane glycoprotein that acts as a ligand for T cell-expressed 267 Cluster of Differentiation 6 (CD6), and is implicated in autoimmune conditions ^[24]. CDCP1 is 268 amenable to modulation by approved drug treatments: Itolizumab, which is used to treat psoriasis, 269 disrupts CDCP1-CD6 binding and downregulates T-cell-mediated inflammation ^[25], whilst 270 atomoxetine, a treatment for attention deficit hyperactivity disorder, which is being considered for 271 the treatment of mild cognitive impairment, reduced cerebrospinal fluid (CSF) CDCP1 levels ^[26]. 272 Intriguingly, findings in mice suggest a functional link between CDCP1 and MOG ^[6].

273 Our study has several strengths. We measured 1160 proteins, associated with a wide range of 274 physiological processes, in a large, well-characterised cohort. Replication analyses, where possible, 275 were performed in an independent cohort in which proteins were measured using an independent 276 methodology. The availability of genetic and brain MRI data permitted an exploration of causality 277 and putative causal pathways. The use of MR to identify potentially causal associations will have offered protection against some of the common confounders of observational analyses ^[27], with the 278 279 use of multiple MR methods, which generally gave concordant estimates of effect, mitigating against the individual biases of different MR methodologies ^[28]. Moreover, by requiring instrumental 280 variables to be located in *cis* to their target protein, we limited the chance of pleiotropic effects ^[29]. 281

282 There are also several limitations to consider.

First, the 1160 proteins measured represent a small subset of the circulating proteome ^[30]. Although these proteins are involved in a wide range of biological functions represented by all 13 Olink Target 96 panels, limitations to our understanding of the proteome mean that is not possible to assess the extent to which these proteins are representative of the rest of the proteome. Replication analyses were only performed for those proteins for which data were available in the GS cohort, meaning that we did not assess replication of CA14 or MOG.

Second, the availability of suitable IVs mean that our primary MR analyses were only performed for CA14, CDCP1, and MOG. Whilst we required a minimum of three IVs for the primary MR analyses, our sensitivity analyses, in which a stricter threshold for independence was applied to the IVs necessitated the use of fewer than three IVs in each analysis. As such, the results of the sensitivity analyses should be interpreted with this caveat in mind.

Third, for all but one pair of traits, we were insufficiently powered to assess co-localisation between genetic variants associated with protein level and cognition, structural brain phenotypes, and disease outcomes. This means that it is possible that significant MR findings might reflect the presence of separate causal variants in linkage disequilibrium (LD) with one another ^[31]

298 Fourth, we measured protein levels in the plasma, rather than in the brain or CSF. It is, however, 299 important to note the striking enrichment for brain-expressed proteins amongst the DSST-associated 300 proteins. Previous analyses of the GS cohort, in which replication was sought in the present study, 301 have identified the levels of several plasma proteins as being associated with multiple markers of brain health^[8]. These findings support the use of the plasma to assess brain-related phenotypes and 302 303 emphasise the need for additional research to explain the mechanisms controlling the efflux of 304 brain-expressed proteins into the bloodstream in non-clinical populations. Moreover, the use of cis pQTLs, which are likely to be shared across tissues ^[32], as IVs in our MR analyses, supports the 305 306 possibility that the MR-identified associations reflect the actions of the proteins-of-interest in the 307 brain.

In summary, we identified protein biomarkers of cognitive function that may causally affect brain structure and risk for stroke and intracranial aneurysm. Notwithstanding the need for replication, our findings prompt several hypotheses that should be assessed by future studies. Our apparently paradoxical findings of higher CA14 levels being associated with both better cognitive function and increased stroke risk suggest that molecular findings can inform a more nuanced understanding of the relationship between premorbid cognitive function and neurological disease risk. It is possible

- that improved risk stratification may be achieved through the combination of cognitive assessment
- and biomarker measurement. The availability of approved drugs targeting our identified proteins
- raises the possibility of drug repurposing for novel therapeutic interventions to prevent cognitive
- 317 decline, stroke, and intracranial aneurysm.

319 4. Methods

320 Sample information

- 321 This study used data from participants of self-reported European (N = 3514), Latin (N = 4309), or
- 322 Persian (N = 1332) ancestry from the Population Urban Rural Epidemiology (PURE) biomarker sub-
- 323 study ^[33] (Supplementary Information). African (n=659), South Asian (n=604), East Asian (n=314),
- 324 and Arab (n=204) participants were excluded to align PURE genetic data with external genetic
- 325 datasets, which are predominantly European. Participants of Latin and Persian ancestry were
- included due to their genetic overlap with European participants ^[33].
- 327 The PURE biomarker study also included European participants enrolled in PURE-MIND (N = 1198)^[10]

328 (Supplementary Information).

The European, Latin, and Persian PURE biomarker cohort participants were used to identify protein biomarker pQTLs ^[33], for use in MR analyses, whilst data from the European PURE-MIND biomarker participants were used for observational association analyses.

We sought replication of our observational findings in GS^[34, 35], which was recruited through re-332 contact of the Generation Scotland: Scottish Family Health Study (GS:SFHS) [36, 37]. GS:SFHS is a 333 334 population- and family-based cohort of >24,000 individuals from Scotland. GS:SFHS participants 335 were recruited between 2006 and 2011. Upon recruitment, participants attended a clinic where 336 detailed health, cognitive, and lifestyle information, and biological samples were collected. Between 337 2015 and 2018, a subset of the GS:SFHS participants completed additional health and cognitive 338 assessments, brain MRI, and provided blood samples for proteomic analysis. Up to 1053 GS 339 participants were available for replication analyses.

340 **Ethical approval**

341 All centres contributing to PURE were required to obtain approval from their respective ethics 342 committees (Institutional Review Boards). Participant data is confidential and only authorized

individuals can access study-related documents. The participants' identities are protected in
documents transmitted to the Coordinating Office, as well as biomarker and genetic data.
Participants provided informed consent to obtain baseline information, and to collect and store
genetic and other biological specimens.

The GS:SFHS obtained ethical approval from the NHS Tayside Committee on Medical Research Ethics, on behalf of the National Health Service (reference: 05/S1401/89). All participants provided broad and enduring written informed consent for biomedical research. GS:SFHS has Research Tissue Bank Status (reference: 15/ES/0040), providing generic ethical approval for a wide range of uses within medical research. The imaging subsample of GS:SFHS (referred to as "GS" herein) received ethical approval from the NHS Tayside committee on research ethics (reference 14/SS/0039). All experimental methods were in accordance with the Helsinki declaration.

354 Assessment of between-cohort differences

Between cohort differences in quantitative variables (age, DSST score, BMI, blood pressure, and brain MRI volumes) were assessed using two-sample t-tests. Categorical variables (sex, education type, and disease status) where the smallest count in any cell of the contingency table was greater than five were assessed using a chi-squared test; otherwise, a Fisher's Exact Test was employed. Statistical significance was defined as p < 0.05.

360 Assessment of cognitive function

General cognitive ability was measured in PURE-MIND and GS by trained assessors using the DSST (Wechsler Adult Intelligence Scale, 3rd Edition)^[38]. The DSST is a pencil and paper test in which participants must match symbols to numbers according to a key. Participants were scored according to the number of correct matches made within two minutes (maximum score: 133). The DSST measures several cognitive functions, including associative learning and executive function^[39], and DSST performance is highly correlated with the general intelligence factor, *g*. PURE-MIND

367 participants completed the Montreal Cognitive Assessment (MoCA) [11], a questionnaire-based test

368 with scores 0 to 30. A score of 26 or higher is considered normal ^[11].

369 Measurement of plasma protein expression

In the PURE biomarker cohort, 1196 plasma protein levels were measured by proximity extension assay using the Olink Proseek Target 96 reagent kit (Olink, Uppsala, Sweden) in 12066 participants (including 3735 European, 4695 Latin, and 1436 Persian). Following pre-processing and quality control steps (**Supplementary Information**), measurements were available for 1160 biomarkers in 8369-9154 European, Latin, or Persian participants (depending on biomarker-specific missingness). In GS, plasma protein levels were measured with the SOMAscan assay platform (SomaLogic Inc.), as described previously ^[40]. Following initial data processing and quality control steps, measures of

377 4058 proteins were available in 1095 participants. Prior to analysis, protein abundance 378 measurements were log-transformed and rank-based inverse normalised.

379 Brain imaging

380 PURE-MIND participants enrolled in the PURE biomarker cohort were scanned at four sites in Canada 381 (three at 1.5T (two on General Electric (GE) scanners, one on a Phillips scanner), one at 3T (GE)). The 382 brain imaging phenotypes assessed in this study were total brain volume (excluding ventricles), total 383 white matter volume, hippocampal volume, average cortical thickness, a multi-region composite 384 thickness measure designed to differentiate Alzheimer's disease patients from clinically normal 385 participants ^[41], silent brain infarcts (SBI), cerebral microbleeds (CMB), and WMH volumes. These will 386 henceforth be referred to as the "structural brain phenotypes". Further information about the 387 derivation of the structural brain phenotypes is available in the **Supplementary Information**.

388 Genotyping and imputation of PURE-MIND

PURE participant genotypes (Thermofisher Axiom Precision Medicine Research Array r.3) were called
 using Axiom Power Tools and in-house scripts. Quality control steps are described in the
 Supplementary Information.

Imputation was performed on the 749,783 genotyped variants following the TOPMed Imputation
 server pipeline (<u>https://imputation.biodatacatalyst.nhlbi.nih.gov/</u>). Further details are in the
 Supplementary Information.

395 Assessment of the association between protein biomarkers and cognitive function and structural 396 imaging phenotypes

397 We assessed the association between standardised protein levels and cognitive and structural brain 398 phenotypes using two-tailed linear (DSST, MoCA, total brain volume, white matter volume, 399 hippocampal volume, WMH volume, cortical thickness) or logistic (CMB, SBI) regression. The 400 cognitive or structural brain phenotype-of-interest was the dependent variable with the standardised protein expression level, age, age², sex, and the first ten genetic principal components 401 402 as independent variables. A sensitivity analysis was performed for DSST-associated proteins in which 403 we further adjusted for education (a categorical variable with levels: (i) no education; (ii) high school 404 or less; (iii) trade school; and (iv) college or university). We calculated Pearson's correlation 405 coefficient to assess the pairwise correlations between DSST-associated proteins. Within each 406 analysis, we applied a Bonferroni correction to determine statistical significance, yielding the following significance thresholds: $p < 4.31 \times 10^{-5}$ when assessing associations with 1160 proteins; $p < 10^{-5}$ 407 2.5 x 10⁻³ when assessing associations with the five DSST-associated proteins across four DSST-408 associated structural brain phenotypes; and $p < 5 \times 10^{-3}$ when assessing 10 pairwise correlations 409 410 between proteins.

411 We performed replication analyses in GS for the significant proteins identified in PURE-MIND. Two-412 tailed mixed effects models were fitted using the lmekin function from the R package coxme v.2.2.17 413 ^[42] to assess the association of the outcome variable (DSST performance, total brain volume

414 (excluding ventricles), cerebral white matter volume, hippocampal volume, and WMH volume) with standardised protein expression, covarying for age, age², sex, study site (Dundee or Aberdeen), the 415 416 delay between blood sampling and protein extraction, depression (a binary variable representing 417 lifetime depression status), and a kinship matrix. When a brain volume phenotype was the outcome 418 variable, additional covariates were included to account for ICV, the interaction between ICV and 419 study site (to account for a site-associated batch effect on ICV measurement), and whether there 420 was manual intervention using tools within Freesurfer during the quality control process. Replication 421 was defined as a concordant direction of effect, meeting a Bonferroni-corrected threshold of p < p1.67 x 10⁻² (accounting for the assessment of three DSST-associated proteins) or $p < 7.14 \times 10^{-3}$ 422 423 (accounting for the assessment of seven structural brain phenotype-protein combinations).

424 Assessment of the association of DSST performance with MRI-derived structural brain phenotypes

To identify mediators of the association between protein expression and DSST performance, we first established the structural brain phenotypes that satisfied the requirements of potential mediators (i.e. associated with both DSST performance and at least one DSST-associated protein), and then formally tested the meditation relationship by bootstrap mediation analyses.

429 We estimated the association between DSST performance and structural brain phenotypes in PURE-430 MIND using linear models. All brain volume measurements were normalised to ICV and the models 431 included covariates for age, age², sex, and the first ten genetic principal components. We defined 432 statistical significance as p < 0.00625 (Bonferroni correction for eight phenotypes; two-tailed) and 433 sought replication of significant associations (N = 5) in GS. In GS, brain volumes were residualised for 434 ICV, scanner location, the interaction between ICV and scanner location, and whether there was 435 manual intervention during the quality control process. The resultant residuals were included as the dependent variable in a mixed effects model with DSST score, age, age², sex, depression, and a 436 437 kinship matrix as independent variables. Statistical significance was defined as p < 0.0125 (two-438 tailed).

The DSST performance-associated brain MRI phenotypes (N = 4) were assessed as potential mediators of the protein level-DSST associations (N = 3, yielding a total of N = 9 mediations to assess) using bootstrap mediation analysis in PURE-MIND. Analyses were performed using the R package "mediation" ^[43] with 1000 bootstraps. We corrected for the nine potential mediation relationships assessed using a Bonferroni-corrected threshold of $p < 5.56 \times 10^{-3}$.

444 Functional and tissue-specific expression enrichment analyses

Proteins associated with DSST performance at p < 0.05 in PURE-MIND were included in functional 445 446 and tissue-specific expression analyses in three groups: (i) all proteins; (ii) positively associated 447 proteins; and (iii) negatively associated proteins. Enrichment was assessed relative to all proteins in 448 our dataset that passed quality control (N =1160). Functional enrichment analyses were performed using WebGestalt (http://www.webgestalt.org/)^[44] using default parameter settings for the over-449 450 representation analysis method to assess enrichment for: (i) gene ontology categories (biological 451 processes, molecular functions, and cellular compartments); (ii) Reactome pathways; and (iii) 452 disease-associated genes (Disgenet). Tissue-specific enrichment analyses were performed using the 453 "GTEx v8: 54 tissue types" and "GTEx v8: 30 general tissue types" gene expression datasets in FUnctional Mapping and Annotation (FUMA)^[45]. For both the functional enrichment and tissue 454 455 expression analyses, enrichment was assessed using a hypergeometric test and significant 456 enrichment was defined as a Benjamini-Hochberg-adjusted p < 0.05, correcting for the number of 457 tests performed within each analysis platform. Analyses were performed using web interfaces 458 accessed on 18/04/2022 (WebGestalt and FUMA) and 14/01/2023 (FUMA).

459 **Two-sample forward MR analyses**

We performed two-sample forward MR analyses to identify potentially causal associations between genetically predicted plasma protein levels and: (i) cognitive function; (ii) structural brain phenotypes (total brain volume, cerebral white matter volume, hippocampal volume, WMH volume,

and CMB); and (iii) disease outcomes (Alzheimer's disease, all stroke, stroke subtypes (ischaemic,

464 cardioembolic, large artery, and small vessel), and intracranial aneurysm).

465 Associations between single nucleotide polymorphisms (SNPs) and plasma protein expression levels

were calculated in PURE (**Supplemental Information**). Following quality control, a set of pQTLs that

467 was independent ($r^2 < 0.1$) in all three populations was retained. Sensitivity analyses were performed

468 in which the pruning threshold was adjusted to $r^2 < 0.01$.

The independent set of pQTLs were assessed for their associations with cognitive function, structural

470 brain phenotypes, and disease outcomes using summary statistics from published studies [46-53].

MR analyses were performed using the R packages MRBase for TwoSample MR v.0.5.6^[54], mr.raps 471 v.0.4.1 ^[55], and MRPRESSO v.1.0 ^[56]. We employed several complementary MR approaches: IVW ^[57]. 472 weighted median^[58], robust adjusted profile scores (RAPS)^[55], MR-Egger^[59], and MR-PRESSO^[56]. We 473 474 adopted the IVW approach as our primary methodology and defined statistical significance using a 475 liberal within-outcome variable Bonferroni correction for the proteins (CA14, CDCP1, and MOG) that 476 could be assessed, yielding a significance threshold of p < 0.0167 (or p < 0.025 or 0.05 when an 477 outcome could only be assessed for two or one protein(s)). Further details of the MR analyses are 478 included in the Supplementary Information.

479 Pairwise Conditional Analysis and Co-localisation Analysis (PWCoCo)

PWCoCo ^[31, 60] was performed to assess the existence of a shared causal variant between (i) pQTLs
for each of the five proteins-of-interest and (ii) variants associated with the outcomes assessed in
the two-sample MR analyses (Supplementary Information).

483 Software

484 Statistical analyses and plot generation were performed in R (versions 3.6.0, 4.1.1, 4.1.2, 4.2.0,
485 4.2.1).

486 Data availability

487 The terms of consent for PURE participants preclude the sharing of individual-level data. Individual 488 level data is available through collaboration with PURE researchers (https://www.phri.ca/research/pure/). Summary-statistics for the analyses presented here are 489 490 available in the supplementary materials.

According to the terms of consent for GS participants, applications for individual-level data must be reviewed by the GS Access Committee (<u>access@generationscotland.org</u>). Complete summary statistics are available in the supplementary materials for the protein-DSST score associations assessed in this study.

495 Code availability

496 The code used to generate the results in this study is available on reasonable request from the 497 corresponding author.

498 Funding and acknowledgements

499 PURE

500 The PURE study is an investigator-initiated study that is funded by the Population Health Research 501 Institute, the Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation of Ontario, 502 support from CIHR's Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, 503 as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from 504 several pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi-505 Aventis [France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and 506 GlaxoSmithKline), and additional contributions from Novartis and King Pharma and from various 507 national or local organisations in participating countries as follows: Argentina-Fundacion ECLA; 508 Bangladesh—Independent University, Bangladesh and Mitra and Associates; Brazil—Unilever Health 509 Institute, Brazil; Canada—Public Health Agency of Canada and Champlain Cardiovascular Disease 510 Prevention Network; Chile—Universidad de la Frontera; Colombia—Colciencias (grant number 6566–

511 04–18062); South Africa—The North-West University, SANPAD (SA and Netherlands Programme for 512 Alternative Development), National Research Foundation, Medical Research Council of South Africa, 513 The South Africa Sugar Association, Faculty of Community and Health Sciences; Sweden-grants 514 from the Swedish State under the Agreement concerning research and education of doctors, the 515 Swedish Heart and Lung Foundation, the Swedish Research Council, the Swedish Council for Health, 516 Working Life and Welfare, King Gustaf V's and Queen Victoria Freemasons Foundation, AFA 517 Insurance, Swedish Council for Working Life and Social Research, Swedish Research Council for 518 Environment, Agricultural Sciences and Spatial Planning, grant from the Swedish State under 519 (LäkarUtbildningsAvtalet) Agreement, and grant from the Västra Götaland Region; and United Arab 520 Emirates-Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences, Dubai Health 521 Authority, Dubai. The PURE biomarker project was supported by Bayer and the CIHR. The biomarker 522 project was led by PURE investigators at the Population Health Research Institute (Hamilton, 523 Canada) in collaboration with Bayer scientists. Bayer directly compensated the Population Health 524 Research Institute for measurement of the biomarker panels, scientific, methodological, and 525 statistical work. Genetic analyses were supported by CIHR (G-18-0022359) and Heart and Stroke 526 Foundation of Canada (application number 399497) in the form of funding to GP.

527 GS

528 This work was supported by the Wellcome Trust [104036/Z/14/Z, 220857/Z/20/Z, and 529 216767/Z/19/Z] and an MRC Mental Health Data Pathfinder Grant [MC PC 17209] to AMM. DAG is 530 funded by the Wellcome Trust Translational Neuroscience PhD Programme at the University of 531 Edinburgh [108890/Z/15/Z]. LS and ANH are supported by Medical Research Council 532 [MR/L023784/2]: Dementias Platform UK. LS is also supported by a Medical Research Council Award 533 to the University of Oxford [MC PC 17215]. AS is supported through the Wellcome-University of 534 Edinburgh Institutional Strategic Support Fund (Reference 204804/Z/16/Z), and indirectly through 535 the Lister Institute of Preventive Medicine award with reference 173096. Generation Scotland

received core support from the Chief Scientist Office of the Scottish Government Health Directorates

537 [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping of the GS:SFHS samples was

538 carried out by the Genetics Core Laboratory at the Clinical Research Facility, Edinburgh, Scotland,

and was funded by the UK's Medical Research Council and the Wellcome Trust [104036/Z/14/Z].

540 We are grateful to all the families who took part in Generation Scotland, the general practitioners

and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation

542 Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers,

research scientists, volunteers, managers, receptionists, healthcare assistants and nurses.

544 We thank Dr Alison Offer for assistance in producing the forest plots.

545 **Conflicts of interest**

546 MC is supported by a Canadian Institute of Health Research doctoral award and has received 547 consulting fees from Bayer AG. MP is supported by the EJ Moran Campbell Internal Career Research 548 Award from McMaster University. DAG is a part-time employee of Optima partners, a health data consultancy based at the Bayes centre, The University of Edinburgh. SH is an employee of Bayer AG. 549 550 AMM has previously received speaker's fees from Illumina and Janssen and research grant funding 551 from The Sackler Trust. SY is supported by the Heart and Stroke Foundation/Marion W Burke Chair in 552 Cardiovascular Disease. GP is supported by the CISCO Professorship in Integrated Health Systems. 553 The other authors declare no competing interests.

555 References

- 556 1. Martin, G.M., *Defeating Dementia*. Nature, 2004. **431**: p. 247-248.
- 557 2. Rostamian, S., S. Mahinrad, T. Stijnen, B. Sabayan, and A.J. de Craen, *Cognitive impairment*
- 558 and risk of stroke: a systematic review and meta-analysis of prospective cohort studies.
- 559 Stroke, 2014. **45**(5): p. 1342-8.
- 560 3. Valenzuela, M.J. and P. Sachdev, *Brain reserve and dementia: a systematic review*. Psychol
 561 Med, 2006. 36(4): p. 441-54.
- 562 4. Pettigrew, C. and A. Soldan, *Defining Cognitive Reserve and Implications for Cognitive Aging*.
 563 Curr Neurol Neurosci Rep, 2019. 19(1): p. 1.
- 564 5. Harris, S.E., S.R. Cox, S. Bell, R.E. Marioni, B.P. Prins, A. Pattie, et al., *Neurology-related* 565 protein biomarkers are associated with cognitive ability and brain volume in older age. Nat 566 Commun, 2020. **11**(1): p. 800.
- Lindbohm, J.V., N. Mars, K.A. Walker, A. Singh-Manoux, G. Livingston, E.J. Brunner, et al.,
 Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. Alzheimers Dement, 2022. 18(4): p. 612-624.
- 570 7. Whelan, C.D., N. Mattsson, M.W. Nagle, S. Vijayaraghavan, C. Hyde, S. Janelidze, et al.,
- 571 *Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's* 572 *disease.* Acta Neuropathol Commun, 2019. **7**(1): p. 169.
- 573 8. Gadd, D.A., R.F. Hillary, D.L. McCartney, L. Shi, A. Stolicyn, N.A. Robertson, et al., *Integrated* 574 *methylome and phenome study of the circulating proteome reveals markers pertinent to* 575 *brain health.* Nat Commun, 2022. **13**(1): p. 4670.
- 576 9. Tin, A., A.E. Fohner, Q. Yang, J.A. Brody, G. Davies, J. Yao, et al., *Identification of circulating*577 proteins associated with general cognitive function among middle-aged and older adults.
 578 Communications Biology, 2023. 6(1): p. 1117.

- 579 10. Smith, E.E., M. O'Donnell, G. Dagenais, S.A. Lear, A. Wielgosz, M. Sharma, et al., *Early*580 *cerebral small vessel disease and brain volume, cognition, and gait.* Ann Neurol, 2015. **77**(2):
 581 p. 251-61.
- 11. Nasreddine, Z.S., N.A. Phillips, V. Bedirian, S. Charbonneau, V. Whitehead, I. Collin, et al., *The*Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J
 Am Geriatr Soc, 2005. 53(4): p. 695-9.
- Lindskog, S., Structure and mechanism of carbonic anhydrase. Pharmacol Ther, 1997. 74(1):
 p. 1-20.
- 587 13. Parkkila, S., A.K. Parkkila, H. Rajaniemi, G.N. Shah, J.H. Grubb, A. Waheed, et al., *Expression*588 of membrane-associated carbonic anhydrase XIV on neurons and axons in mouse and human
 589 brain. Proc Natl Acad Sci U S A, 2001. **98**(4): p. 1918-23.
- 590 14. Chen, J.C. and M. Chesler, *pH transients evoked by excitatory synaptic transmission are*591 *increased by inhibition of extracellular carbonic anhydrase.* Proc Natl Acad Sci U S A, 1992.
 592 89(16): p. 7786-90.
- 593 15. Shah, G.N., B. Ulmasov, A. Waheed, T. Becker, S. Makani, N. Svichar, et al., *Carbonic*594 *anhydrase IV and XIV knockout mice: roles of the respective carbonic anhydrases in buffering*595 *the extracellular space in brain.* Proc Natl Acad Sci U S A, 2005. **102**(46): p. 16771-6.
- 596 16. Provensi, G., F. Carta, A. Nocentini, C.T. Supuran, F. Casamenti, M.B. Passani, et al., *A New*
- 597 Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer's Disease. Int J
 598 Mol Sci, 2019. 20(19).
- Lemon, N., E. Canepa, M.A. Ilies, and S. Fossati, *Carbonic Anhydrases as Potential Targets Against Neurovascular Unit Dysfunction in Alzheimer's Disease and Stroke*. Front Aging
 Neurosci, 2021. 13: p. 772278.
- Sorg, B.A., S. Berretta, J.M. Blacktop, J.W. Fawcett, H. Kitagawa, J.C. Kwok, et al., *Casting a Wide Net: Role of Perineuronal Nets in Neural Plasticity*. J Neurosci, 2016. 36(45): p. 1145911468.

- 605 19. Brakebusch, C., C.I. Seidenbecher, F. Asztely, U. Rauch, H. Matthies, H. Meyer, et al.,
- 606 Brevican-deficient mice display impaired hippocampal CA1 long-term potentiation but show
- 607 no obvious deficits in learning and memory. Mol Cell Biol, 2002. 22(21): p. 7417-27.
- Zhou, X.H., C. Brakebusch, H. Matthies, T. Oohashi, E. Hirsch, M. Moser, et al., *Neurocan is dispensable for brain development.* Mol Cell Biol, 2001. 21(17): p. 5970-8.
- 610 21. Gottschling, C., D. Wegrzyn, B. Denecke, and A. Faissner, Elimination of the four extracellular
- 611 *matrix molecules tenascin-C, tenascin-R, brevican and neurocan alters the ratio of excitatory*
- 612 and inhibitory synapses. Sci Rep, 2019. **9**(1): p. 13939.
- 613 22. Marioni, R.E., S.E. Harris, Q. Zhang, A.F. McRae, S.P. Hagenaars, W.D. Hill, et al., *GWAS on* 614 *family history of Alzheimer's disease*. Transl Psychiatry, 2018. **8**(1): p. 99.
- 615 23. Peschl, P., M. Bradl, R. Hoftberger, T. Berger, and M. Reindl, *Myelin Oligodendrocyte*616 *Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.* Front Immunol,
 617 2017. 8: p. 529.
- Enyindah-Asonye, G., Y. Li, J.H. Ruth, D.S. Spassov, K.E. Hebron, A. Zijlstra, et al., *CD318 is a ligand for CD6.* Proc Natl Acad Sci U S A, 2017. **114**(33): p. E6912-E6921.
- 620 25. Dogra, S., S. Uprety, and S.H. Suresh, *Itolizumab, a novel anti-CD6 monoclonal antibody: a*621 safe and efficacious biologic agent for management of psoriasis. Expert Opin Biol Ther, 2017.
- 622 **17**(3): p. 395-402.
- Levey, A.I., D. Qiu, L. Zhao, W.T. Hu, D.M. Duong, L. Higginbotham, et al., A phase II study
 repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain, 2022.
 145(6): p. 1924-1938.
- Lawlor, D.A., R.M. Harbord, J.A. Sterne, N. Timpson, and G. Davey Smith, *Mendelian randomization: using genes as instruments for making causal inferences in epidemiology.*Stat Med, 2008. 27(8): p. 1133-63.
- Slob, E.A.W. and S. Burgess, A comparison of robust Mendelian randomization methods
 using summary data. Genet Epidemiol, 2020. 44(4): p. 313-329.

- 631 29. Swerdlow, D.I., K.B. Kuchenbaecker, S. Shah, R. Sofat, M.V. Holmes, J. White, et al., Selecting
- 632 instruments for Mendelian randomization in the wake of genome-wide association studies.
- 633 Int J Epidemiol, 2016. **45**(5): p. 1600-1616.
- Omenn, G.S., L. Lane, C.M. Overall, F.J. Corrales, J.M. Schwenk, Y.K. Paik, et al., *Progress on Identifying and Characterizing the Human Proteome: 2018 Metrics from the HUPO Human Proteome Project.* J Proteome Res, 2018. **17**(12): p. 4031-4041.
- 31. Zheng, J., V. Haberland, D. Baird, V. Walker, P.C. Haycock, M.R. Hurle, et al., *Phenome-wide*Mendelian randomization mapping the influence of the plasma proteome on complex
 diseases. Nat Genet, 2020. 52(10): p. 1122-1131.
- Yang, C., F.H.G. Farias, L. Ibanez, A. Suhy, B. Sadler, M.V. Fernandez, et al., *Genomic atlas of*the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological
 disorders. Nat Neurosci, 2021. 24(9): p. 1302-1312.
- 643 33. Narula, S., S. Yusuf, M. Chong, C. Ramasundarahettige, S. Rangarajan, S.I. Bangdiwala, et al.,
 644 *Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis.* Lancet,

645 2020. **396**(10256): p. 968-976.

- Habota, T., A.L. Sandu, G.D. Waiter, C.J. McNeil, J.D. Steele, J.A. Macfarlane, et al., Cohort
 profile for the STratifying Resilience and Depression Longitudinally (STRADL) study: A
 depression-focused investigation of Generation Scotland, using detailed clinical, cognitive,
- 649 *and neuroimaging assessments*. Wellcome Open Res, 2021. **4**: p. 185.
- 650 35. Navrady, L.B., M.K. Wolters, D.J. MacIntyre, T.K. Clarke, A.I. Campbell, A.D. Murray, et al.,
 651 *Cohort Profile: Stratifying Resilience and Depression Longitudinally (STRADL): a questionnaire*
- 652 follow-up of Generation Scotland: Scottish Family Health Study (GS:SFHS). Int J Epidemiol,
- 653 2018. **47**(1): p. 13-14g.
- Smith, B.H., A. Campbell, P. Linksted, B. Fitzpatrick, C. Jackson, S.M. Kerr, et al., Cohort *Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its*

- 656 participants and their potential for genetic research on health and illness. Int J Epidemiol,
- 657 2013. **42**(3): p. 689-700.
- Smith, B.H., H. Campbell, D. Blackwood, J. Connell, M. Connor, I.J. Deary, et al., *Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability.* BMC Med Genet, 2006. **7**: p. 74.
- 38. Wechsler, D., Wechsler Adult Intelligence Scale-Third Edition (WAIS-III). 1997, San Antonio:
 Harcourt Assessment Inc.
- 39. Jaeger, J., Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in
 Neuropsychological Testing. J Clin Psychopharmacol, 2018. 38(5): p. 513-519.
- 665 40. Shi, L., N.J. Buckley, I. Bos, S. Engelborghs, K. Sleegers, G.B. Frisoni, et al., *Plasma Proteomic*666 *Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies.*667 Front Aging Neurosci, 2021. 13: p. 712545.
- Schwarz, C.G., J.L. Gunter, H.J. Wiste, S.A. Przybelski, S.D. Weigand, C.P. Ward, et al., A largescale comparison of cortical thickness and volume methods for measuring Alzheimer's
- 670 *disease severity*. Neuroimage Clin, 2016. **11**: p. 802-812.
- 42. Therneau, T.M., *coxme: mixed effects Cox models.* 2012. p. R Package.
- 43. Tingley, D., T. Yamamoto, K. Hirose, L. Keele, and K. Imai, *mediation: R Package for Causal*673 *Mediation Analysis.* Journal of Statistical Software, 2014. 59(5).
- 44. Liao, Y., J. Wang, E.J. Jaehnig, Z. Shi, and B. Zhang, *WebGestalt 2019: gene set analysis toolkit*with revamped UIs and APIs. Nucleic Acids Res, 2019. 47(W1): p. W199-W205.
- Watanabe, K., E. Taskesen, A. van Bochoven, and D. Posthuma, *Functional mapping and annotation of genetic associations with FUMA*. Nat Commun, 2017. 8(1): p. 1826.
- 678 46. Savage, J.E., P.R. Jansen, S. Stringer, K. Watanabe, J. Bryois, C.A. de Leeuw, et al., Genome-
- wide association meta-analysis in 269,867 individuals identifies new genetic and functional
 links to intelligence. Nat Genet, 2018. 50(7): p. 912-919.

- 681 47. Smith, S.M., G. Douaud, W. Chen, T. Hanayik, F. Alfaro-Almagro, K. Sharp, et al., An expanded
- 682 set of genome-wide association studies of brain imaging phenotypes in UK Biobank. Nat

683 Neurosci, 2021. **24**(5): p. 737-745.

- 48. Hibar, D.P., H.H.H. Adams, N. Jahanshad, G. Chauhan, J.L. Stein, E. Hofer, et al., Novel genetic
 loci associated with hippocampal volume. Nat Commun, 2017. 8: p. 13624.
- 686 49. Persyn, E., K.B. Hanscombe, J.M.M. Howson, C.M. Lewis, M. Traylor, and H.S. Markus,
- 687 *Genome-wide association study of MRI markers of cerebral small vessel disease in 42,310* 688 *participants.* Nat Commun, 2020. **11**(1): p. 2175.
- Knol, M.J., D. Lu, M. Traylor, H.H.H. Adams, J.R.J. Romero, A.V. Smith, et al., Association of *common genetic variants with brain microbleeds: A genome-wide association study.*Neurology, 2020. 95(24): p. e3331-e3343.
- 692 51. Bellenguez, C., F. Kucukali, I.E. Jansen, L. Kleineidam, S. Moreno-Grau, N. Amin, et al., New
 693 insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet,
 694 2022. 54(4): p. 412-436.
- Mishra, A., R. Malik, T. Hachiya, T. Jurgenson, S. Namba, D.C. Posner, et al., *Stroke genetics informs drug discovery and risk prediction across ancestries*. Nature, 2022. 611(7934): p.
- 697115-123.
- 53. Bakker, M.K., R.A.A. van der Spek, W. van Rheenen, S. Morel, R. Bourcier, I.C. Hostettler, et
 al., *Genome-wide association study of intracranial aneurysms identifies 17 risk loci and qenetic overlap with clinical risk factors.* Nat Genet, 2020. **52**(12): p. 1303-1313.
- For Stephen S
- 703 55. Zhao, Q., J. Wang, G. Hemani, J. Bowden, and D.S. Small, *Statistical inference in two-sample*704 *summary-data Mendelian randomization using robust adjusted profile score*. The Annals of
 705 Statistics, 2020. 48(3): p. 1742-1769, 28.

- 706 56. Verbanck, M., C.Y. Chen, B. Neale, and R. Do, Detection of widespread horizontal pleiotropy
- 707 in causal relationships inferred from Mendelian randomization between complex traits and

708 *diseases.* Nat Genet, 2018. **50**(5): p. 693-698.

- Burgess, S., A. Butterworth, and S.G. Thompson, *Mendelian randomization analysis with multiple genetic variants using summarized data*. Genet Epidemiol, 2013. **37**(7): p. 658-65.
- 711 58. Bowden, J., G. Davey Smith, P.C. Haycock, and S. Burgess, *Consistent Estimation in*
- 712 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
 713 Estimator. Genet Epidemiol, 2016. 40(4): p. 304-14.
- 59. Burgess, S. and S.G. Thompson, *Interpreting findings from Mendelian randomization using*the MR-Egger method. Eur J Epidemiol, 2017. **32**(5): p. 377-389.
- Robinson, J.W., G. Hemani, M.S. Babaei, Y. Huang, D.A. Baird, E.A. Tsai, et al., An efficient
 and robust tool for colocalisation: Pair-wise Conditional and Colocalisation (PWCoCo).
 bioRxiv, 2022: p. 2022.08.08.503158.

720 Figure legends

721 Figure 1. Overview of the study design. This study involved European (N = 3514), Latin (N = 4309), 722 and Persian (N = 1332) PURE participants for whom genetic and plasma proteomic data were 723 available. Observational analyses to detect plasma biomarkers of cognitive function were performed 724 in the subset of these participants who were enrolled in the PURE-MIND sub-study (N = 1198), for 725 whom plasma protein (N = 1060 proteins) and MRI measurements were available. Mediation 726 analyses were performed to assess whether any observed associations between protein levels and 727 cognitive function were mediated by structural brain phenotypes ascertained by MRI. Finally, two-728 sample Mendelian randomisation analyses were performed to assess potentially causal effects of 729 genetically-predicted cognition-associated protein levels on genetically-predicted neurological 730 outcomes. For these analyses, genetic instrumental variables for protein levels were identified in the 731 European, Latin, and Persian PURE participants, and associations with neurological outcomes were 732 assessed using external (non-PURE) datasets.

733 Figure 2. Manhattan plot indicating associations between the levels of plasma proteins and 734 performance on the DSST in participants from the PURE-MIND cohort (N = 1198). Each protein is 735 represented by a triangle with upwards-facing triangles indicating a positive association with DSST 736 performance and downwards-facing triangles indicating a negative association with DSST 737 performance. The position of each protein on the x-axis is determined by the genomic location of its 738 corresponding gene and the position on the y-axis is determined by the $-\log_{10} p$ -value. The dashed 739 horizontal line indicates the Bonferroni-corrected significance threshold ($p = 4.31 \times 10^{-5}$) required to 740 maintain a 5% type I error rate.

Figure 3. Forest plot indicating the association between protein levels and DSST performance for significantly associated proteins. For each protein, the difference in DSST score associated with a standard deviation higher level of protein is shown, together with the 95% confidence interval. Abbreviations: BCAN: brevican; CA14: carbonic anhydrase 14; CDCP1: CUB-domain containing

protein 1; CI: confidence interval; GS: Generation Scotland imaging subsample; MOG: myelin
oligodendrocyte glycoprotein; NCAN: neurocan; PURE: Prospective Urban and Rural Epidemiology
study.

748	Figure 4. Forest plots	indicating the	e association b	etween the leve	els of DSST-asso	ciated proteins and
749	DSST-associated stru	ctural brain pl	nenotype. For	each protein, tl	he effect estima	ate (change in brain
750	volume (cm ³ or %) pe	r standard dev	viation increas	e in protein exp	ression) is show	n, together with the
751	95% confidence inter	val. Abbreviat	ions: BCAN: br	evican; CA14: ca	arbonic anhydra	se 14; CDCP1: CUB-
752	domain containing p	rotein 1; Cl: c	onfidence inte	rval; GS: Gener	ation Scotland i	maging subsample;
753	MOG: myelin oligode	endrocyte glyc	oprotein; NCA	N: neurocan; P	URE: Prospectiv	ve Urban and Rural
754	Epidemiology	study;	WMH:	white	matter	hyperintensity.

Table 1. Demographic information for the discovery sample (PURE-MIND) and the replication sample (GS). Basic sample demographic information is
 presented together with information on relevant clinical characteristics, cognitive performance, and structural brain imaging measures. The number of
 participants for whom information was available for each variable are indicated in the "N" columns. In GS, there were participants with missing information
 for smoking (N = 31), hypertension (N = 2), diabetes (N = 1), stroke (N = 1), and depression (N = 2). *PURE-MIND: college or university; GS: university. For

variables that were measured in both cohorts, a statistical comparison was performed and significant *p*-values (*p* < 0.05) are indicated in bold.

	PURE-	PURE-MIND		iS	Test statistic (degrees of freedom)	<i>p</i> -value
	N (%)	Mean (SD)	N (%)	Mean (SD)	_	
Age (years)	1198	54.5 (8.05)	1053	59.9 (9.59)	<i>t</i> = 14.5 (df = 2249)	< 2.2 x 10 ⁻¹⁶
Sex						
Female	709 (59.2%)		627 (59.5%)		χ2 = 0.0173	0.895
Male	489 (40.8%)		426 (40.5%)		_	
Education (highest level achieved)						
High school or less	346 (28.9%)		316 (29.9%)		Fisher's exact test	5.0 x 10 ⁻⁴
Trade school	83 (6.93%)		328 (31.1%)		_	
College/university*	768 (64.1%)		295 (28.0%)		_	

Other	NA		21 (1.99%)			
Unknown	1 (0.0835%)		94 (8.93%)		-	
Clinical characteristics						
Current/former smoker	583 (48.7%)		466 (45.6%)		χ2 = 1.96	0.161
Non-smoker	615 (51.3%)		556 (54.4%)			
Body mass index (kg/m ²)	1193	27.1 (5.15)	1053	28.2 (5.72)	<i>t</i> = 5.06 (df = 2244)	4.92 x 10 ^{.7}
		0.870			N/A	
Waist hip ratio	1192	(0.0965)				
Systolic blood pressure	1197	130 (18.8)	1051	141 (18.9)	<i>t</i> = -13.8 (df = 2246)	< 2.2 x 10 ⁻¹⁶
Diastolic blood pressure	1197	80.9 (11.3)	1051	82.4 (10.8)	<i>t</i> = -3.21 (df = 2246)	1.37 x 10 ⁻³
Hypertension	270 (22.5%)				N/A	
Total cholesterol (mmol/L)	1197	5.52 (1.11)			N/A	
High density lipoprotein cholesterol (mmol/L)	1197	1.47 (0.399)			N/A	
Low density lipoprotein cholesterol (mmol/L)	1187	3.35 (0.882)			N/A	
Diabetes	61 (5.09%)		73 (6.93%)		χ2 = 3.09 (df = 1)	0.0787
Stroke	3 (0.250%)		27 (2.56%)		Fisher's exact test	8.53 x 10 ⁻⁷
Cardiovascular disease	36 (3.00%)		103 (9.78%)		χ2 = 43.3 (df = 1)	4.80 x 10 ⁻¹¹

Depression	NA		336 (31.9%)		N/A	
Cognitive tests	I		L			
Digit Symbol Substitution Test (no. correct in				68.1 (15.2)	<i>t</i> = -2.18 (df = 2249)	0.0298
two minutes)	1198	69.5 (15.3)	1053			
Montreal Cognitive Assessment (no. items					N/A	
correct)	1198	26.5 (2.39)				
Brain Imaging Measures	Brain Imaging Measures					
Cortical thickness (mm)	1198	2.35 (0.0891)			N/A	
Total brain volume without ventricles (cm ³)	1198	1058 (110)	943	1069 (109)	<i>t</i> = -2.31 (df = 2139)	0.0212
Total cerebral white matter volume (cm ³)	1198	447 (60.5)	939	455 (56.9)	<i>t</i> = -3.11 (df = 2135)	1.87 x 10 ⁻³
Total hippocampal volume (cm³)	1198	3.92 (0.433)	941	4.18 (0.437)	<i>t</i> = -13.7 (df = 2137)	< 2.2 x 10 ^{.16}
WMH volume (log-transformed cm ³)	1198	0.751 (0.693)	934	0.777 (0.789)	<i>t</i> = -0.807 (df = 2130)	0.419
Estimated intracranial volume (cm ³)	1198	1491 (159)	944	1400 (225)	<i>t</i> = 11.0 (df = 2140)	< 2.2 x 10 ^{.16}
Silent brain infarct	95 (7.93%)				N/A	
Cerebral microbleeds	86 (7.18%)				N/A	

762 Abbreviations: GS: Generation Scotland; PURE: Prospective Urban and Rural Epidemiology study; SD: standard deviation; WMH: white matter

763 hyperintensities







Effect estimate (95% CI)

Effect estimate (95% CI)

Phenotype

PURE-MIND (N = 1168-1198)

GS (N = 932-939)

